Johnson & Johnson (NYSE:JNJ) Stock Price Up 1.4% – Still a Buy?

Johnson & Johnson (NYSE:JNJ) was up 1.4% on Thursday . The company traded as high as $239.58 and last traded at $237.6630. Approximately 10,231,111 shares were traded during trading, an increase of 8% from the average daily volume of 9,490,200 shares. The stock had previously closed at $234.47.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Stifel Nicolaus raised their price objective on Johnson & Johnson from $205.00 to $220.00 and gave the company a “hold” rating in a report on Thursday, January 22nd. TD Cowen lifted their price target on shares of Johnson & Johnson from $222.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, January 22nd. HSBC upped their price objective on shares of Johnson & Johnson from $240.00 to $265.00 and gave the company a “buy” rating in a research note on Friday, January 30th. Daiwa Capital Markets lifted their target price on shares of Johnson & Johnson from $203.00 to $237.00 and gave the stock an “outperform” rating in a research report on Thursday, January 29th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, December 11th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $233.73.

Johnson & Johnson Trading Up 1.4%

The company has a market capitalization of $572.60 billion, a PE ratio of 21.51, a price-to-earnings-growth ratio of 2.26 and a beta of 0.35. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The stock’s fifty day moving average price is $212.27 and its two-hundred day moving average price is $193.02.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 21st. The company reported $2.46 earnings per share for the quarter, hitting analysts’ consensus estimates of $2.46. The firm had revenue of $24.56 billion for the quarter, compared to analyst estimates of $24.14 billion. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The business’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period last year, the company earned $2.04 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.2%. Johnson & Johnson’s payout ratio is currently 47.06%.

Institutional Trading of Johnson & Johnson

A number of hedge funds have recently modified their holdings of the business. Abich Financial Wealth Management LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter worth approximately $26,000. Cresta Advisors Ltd. purchased a new position in Johnson & Johnson during the fourth quarter valued at $26,000. Evolution Wealth Management Inc. bought a new stake in Johnson & Johnson in the second quarter worth $27,000. Clayton Financial Group LLC purchased a new stake in shares of Johnson & Johnson in the third quarter worth $28,000. Finally, DecisionPoint Financial LLC increased its holdings in shares of Johnson & Johnson by 104.2% during the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after acquiring an additional 75 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.